Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

About Galera SOM trial. Difficult to say how comparable Galera's trial is. For indecipherable reason they introduce results below 60 Gy with slightly better incidence reduction than overall (36 vs 34 %). Stressing results below 60 Gy is strange, because the traditional target for cumulative radiation in treatment of head and neck cancer is 72 Gy making 60 Gy subjects about a week shy of full treatment.

IPIX and Soligenix, for instance, excluded from analysis everybody below 55 Gy. Making any comparison to Galera at this point useless.

BTW: Galera had more than 200 subjects in phase 2b trial. Not much to quibble about the size.